Sep 2026· Frontiers in Public Health· Vol 14· 0 citations· 20 references
Medicine
TL;DR
Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile.
Abstract
Background Poliomyelitis remains a public health concern in select regions. Sabin strain-derived inactivated poliovirus vaccine (sIPV) offers a potentially safer and cost-effective alternative to conventional IPV (cIPV) for adult booster immunization. Objective To systematically review and meta-analyze evidence on the safety of sIPV in adults. Methods We searched PubMed, Embase, Cochrane, and Scopus through January 2026 for randomized controlled trials comparing sIPV with cIPV/w-IPV or placebo in adults. Safety outcomes included local and systemic adverse events: pain, erythema, induration, fever, headache, malaise, and allergic reactions. Data extraction and risk of bias assessment were independently performed. Meta-analysis was conducted using random-effects models in RevMan 5.4, reporting risk ratios (RR) with 95% confidence intervals (CI). Evidence certainty was assessed using GRADE. Results Four trials encompassing 70–340 adults were included. Pooled analyses demonstrated no statistically significant differences in any adverse events between sIPV and cIPV: pain (RR 1.57, 95% CI 0.98–2.50), erythema (RR 1.54, 95% CI 0.64–3.69), induration (RR 0.33, 95% CI 0.04–3.06), fever (RR 0.96, 95% CI 0.39–2.33), headache (RR 0.70, 95% CI 0.21–2.37), and malaise (RR 0.75, 95% CI 0.17–3.27). Heterogeneity was negligible (I2 = 0%). Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile. Certainty of evidence was low to very low due to small sample sizes and imprecision. Conclusion sIPV demonstrates a safety profile comparable to conventional IPV in adult booster recipients, supporting its use as a viable alternative in polio eradication strategies. Further large-scale and long-term studies are warranted to confirm these findings. Systematic Review Registration identifier: CRD420261329648.
ABSTRACT Individual studies indicate stronger and persistent long-term immunogenicity with TZ84-based than HM175-based hepatitis A vaccines. This systematic review and meta-analysis compared immunogenicity and safety of inactivated TZ84- and HM175-based hepatitis A vaccines in children and adolescents. Studies involvin...
R. Kundu, A. Ghosh, A. Toppo et al.· Human Vaccines & Immunothera...· 0 citations
ABSTRACT Background Respiratory syncytial virus (RSV) is among the leading causes of lower respiratory tract illness in newborns worldwide. This study reviews evidence on the efficacy and safety of maternal RSV vaccination. Methods PROSPERO registered this PRISMA-compliant systematic review (CRD42024566335). Keywords a...
Khawla Abu Hammour, Qusai Manaseer, Murad Dweik et al.· Journal of Pharmaceutical Po...· 0 citations
Background/Objectives: Adults eligible for respiratory syncytial virus (RSV) vaccination may also receive influenza, COVID-19, pneumococcal, or herpes zoster vaccines. We compared immunogenicity and safety between coadministration and sequential schedules. Methods: We searched PubMed, Embase, Web of Science, Scopus, an...
Shun-Chang Jiang, Yan Liu, Ran Cui· Vaccines· 0 citations
Dengue vaccines were generally well tolerated, with most adverse events being mild to moderate during follow-up, and future attempts should focus on developing Dengue vaccines that provide safe, balanced, and durable protection against all four Dengue virus serotypes while minimizing the risk of antibody-dependent enha...
D. Zaçe, A. Cekrezi, Martina Leone et al.· Le infezioni in medicina· 1 citation
Overall, co-administration preserves influenza immunogenicity but modestly reduces COVID-19 vaccine GMFR and the low absolute risk difference supports its feasibility as a strategy to streamline vaccination schedules and improve uptake.
Samuel Asri, P. Fragkou, E. Ahrens et al.· npj Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.